Community stack
KLOW Stack
KPV + GHK-Cu + BPC-157 + TB-500
KLOW is marketed as GLOW plus a dedicated anti-inflammatory layer: the same tissue-repair and skin goals (connective tissue, skin remodeling, recovery) with KPV added specifically for gut-barrier integrity and calming inflammatory signaling.
Community stack - not clinically tested
No clinical trial has tested this exact combination. The rationale below is built from each compound's individual research, and the dosing is community-derived. None of these compounds is FDA-approved for this use.
What is in it
Why people run it
Both sources fetched frame KLOW as solving two separate problems at once - structural repair (handled by GHK-Cu, BPC-157 and TB-500 rebuilding collagen, vasculature and tissue) and inflammation (handled by KPV). Peptide Dosing Protocols is explicit that KPV is included because it 'is the only one of the four that targets NF-kB-driven cytokine production directly,' where the other three are described as reducing inflammation only as a secondary effect of repair. This traces to KPV's established role as a tripeptide fragment of alpha-MSH with documented anti-inflammatory, NF-kB-linked activity, layered onto the same GHK-Cu/BPC-157/TB-500 rationale used for GLOW.
Community dosing
communityThe most detailed protocol found (Peptide Dosing Protocols) reconstitutes an 80 mg combined vial (50 mg GHK-Cu plus 10 mg each of KPV, BPC-157 and TB-500) with 3 mL bacteriostatic water, dosed once daily subcutaneously and titrated from about 2 mg total per day in weeks 1-2 up to about 6 mg total per day by weeks 5-8, run in 4-6 week on-cycles with 2-4 week breaks (cited as a copper-accumulation precaution given the GHK-Cu content). AgeRejuvenation's clinic page, by contrast, declines to publish a universal dose, saying it depends on individual testing and history.
Work out your draw in the calculatorThe honest caveat
Both sources are direct on this point: Peptide Dosing Protocols states 'No published clinical trial has evaluated the four-peptide KLOW combination together,' and AgeRejuvenation notes the blend 'has not been studied as a fixed blend' the way an approved drug would be, with claims framed as 'may-support effects studied in the individual peptides, not guaranteed outcomes.' Everything above sits at the level of each individual peptide's research, not the four-peptide mix, and none of the four is FDA-approved.
Sources
- [1]KLOW Dosing Guide: GHK-Cu + KPV + BPC-157 + TB-500 Protocol and ReconstitutionStates 'No published clinical trial has evaluated the four-peptide KLOW combination together'; explains KPV's inclusion as the only compound of the four that 'targets NF-kB-driven cytokine production directly'; gives reconstitution (80 mg vial + 3 mL bacteriostatic water) and titration dosing (2 mg to 6 mg total/day over 8 weeks, 4-6 weeks on/2-4 off).
- [2]KLOW Peptide Stack: GHK-Cu, BPC-157, TB-500, KPVStates the four-peptide blend 'has not been studied as a fixed blend' the way an approved drug would be, and that research sits 'largely at the level of the individual peptides rather than the four-peptide combination'; declines to publish a universal dose, individualizing it per patient.
Other stacks